Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Paclitaxel plus Epirubicin in metastatic breast cancer is a recommended scheme in National
Comprehensive Cancer Network (NCCN) guideline. Paclitaxel in Combination with Carboplatin is
also effective in Metastatic Breast Cancer (MBC) in some clinical study with small sample.
Phase:
Phase 4
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital